New immunotherapy combo aims to boost hodgkin lymphoma remission
NCT ID NCT05949931
First seen May 13, 2026 · Last updated Jun 20, 2026 · Updated 7 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug penpulimab to standard AVD chemotherapy improves outcomes for people with newly-diagnosed advanced classic Hodgkin lymphoma. About 108 adults will receive either concurrent or sequential treatment. The main goal is to see how many patients achieve complete remission after all treatment cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Penpulimab (an immunotherapy drug) combined with AVD chemotherapy
What this could lead to
If successful, this could offer a more effective first-line treatment for advanced Hodgkin lymphoma, potentially improving remission rates.
What could go wrong
This is an early-phase (Phase 2) trial with only 108 participants, so results may not apply broadly. Side effects from the drug combination are possible and not yet fully known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.